Bionor Pharma ASA (BNRPF) 0.3800 $BNRPF Global Hepatitis

New Post Public Reply Private Reply Replies (0) Message Board

Jul 12, 2015 at 4:53 AM

Bionor Pharma ASA (BNRPF) 0.3800 $BNRPF

Global Hepatitis C Pipeline Report 2015 - 103 Companies & 251 Drug Profiles
M2 - Wed May 20, 4:32AM CDT
Research and Markets (http://www.researchandmarkets.com/research/96rn9k/hepatitis_c) has announced the addition of the "Hepatitis C - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Hepatitis C, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hepatitis C and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - 30 of the 100 Companies - 3-V Biosciences, Inc. - AbbVie Inc. - Achillion Pharmaceuticals, Inc. - Adaptimmune Limited - AiCuris GmbH & Co. KG - AIMM Therapeutics B.V. - Akshaya Bio Inc. - Alnylam Pharmaceuticals, Inc. - Altor BioScience Corporation - Amarna Therapeutics B.V. - American Gene Technologies International Inc. - Anacor Pharmaceuticals, Inc. - ARA Healthcare Pvt. Ltd. - Arrowhead Research Corporation - Ascendis Pharma A/S - Astex Pharmaceuticals, Inc. - Biogenomics Limited - BioLineRx, Ltd. - Bionor Pharma ASA - Biotest AG - Biotron Limited - Bolder Biotechnology, Inc. - Bristol-Myers Squibb Company - Celgene Corporation - Chiasma, Inc. - Chugai Pharmaceutical Co., Ltd. - Cocrystal Pharma, Inc. - Conatus Pharmaceuticals Inc. - Crucell N.V. - Debiopharm International S.A. For more information visit http://www.researchandmarkets.com/research/96...epatitis_c
ASND: 19.38 (-0.22), ARWR: 6.68 (+0.07), ACHN: 8.68 (+0.14), CNAT: 4.83 (-0.09), ANAC: 84.61 (+1.95), ABBV: 69.23 (+1.26), BMY: 69.27 (+1.38), CELGZ: 2.15 (+0.14)

HIV-1 Infection - Pipeline Review, H1 2015
M2 - Wed May 13, 5:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wrjl97/hiv1_infection) has announced the addition of the "HIV-1 Infection - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for HIV-1 Infection, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for HIV-1 Infection and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AlphaVax, Inc. - AltraVax Inc. - Aphios Corporation - Argos Therapeutics, Inc. - Bionor Pharma ASA - Biosantech SA - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - CompleGen, Inc. - Critical Outcome Technologies Inc. - CytoDyn Inc. - Enzo Biochem, Inc. - FIT Biotech Oy - GeneCure LLC - Gilead Sciences, Inc. - GlaxoSmithKline plc - Heat Biologics, Inc. - InnaVirVax SA - Inovio Pharmaceuticals, Inc. - Johnson & Johnson - Merck & Co., Inc. - Mymetics Corporation - Myrexis, Inc. - Oncovir, Inc. - OyaGen Inc. - Peregrine Pharmaceuticals, Inc. - Pfizer Inc. - Pharis Biotec GmbH - United Biomedical, Inc. - Valens Therapeutics, Inc. - Vichem Chemie Research Ltd. - ViiV Healthcare Limited For more information visit http://www.researchandmarkets.com/research/wr..._infection
HTBX: 6.35 (+0.02), PFE: 34.36 (+0.50), BMY: 69.27 (+1.38), GSK: 42.45 (+0.65), ARGS: 6.45 (+0.69), INO: 7.46 (+0.19), JNJ: 99.53 (+1.13), ENZ: 3.00 (+0.04), GILD: 113.74 (+0.38), MRK: 57.95 (+0.57)

H1N1 Infection Pipeline Review 2015 - Analysis of 32 Companies & 55 Drug Profiles
M2 - Mon Apr 27, 11:06AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3glbfl/h1n1_infection) has announced the addition of the "H1N1 Infection - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for H1N1 Infection, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for H1N1 Infection and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Adamas Pharmaceuticals, Inc. - Akshaya Bio Inc. - AlphaVax, Inc. - Antigen Express, Inc. - Beijing Minhai Biotechnology Co., Ltd - Bionor Pharma ASA - CEL-SCI Corporation - Cilian AG - Colby Pharmaceutical Company - Crucell N.V. - EpiVax, Inc. - Etubics Corporation - Gemmus Pharma Inc. - iBio, Inc. - Inovio Pharmaceuticals, Inc. - Johnson & Johnson - Kineta, Inc. - Kyowa Hakko Kirin Co., Ltd. - Medicago Inc. - NanoViricides, Inc. - Onxeo SA - OPKO Health, Inc. - REPLICor Inc. - Revivicor, Inc. - Sarepta Therapeutics, Inc. - Sirnaomics, Inc. - TaiMed Biologics Inc. - Takeda Pharmaceutical Company Limited - TechnoVax, Inc. - Vaxart, Inc. - Vaxin, Inc. - Vaxine Pty Ltd For more information visit http://www.researchandmarkets.com/research/3g..._infection
JNJ: 99.53 (+1.13), INO: 7.46 (+0.19), CVM: 0.67 (+0.04), OPK: 16.55 (-0.01), SRPT: 30.02 (+0.66), IBIO: 0.86 (+0.01), NNVC: 1.56 (-0.04)

Next Week In Biotech: Arena And Vivus Report, Radiesse And Avedro Ad Comms
SA Editor Mike Taylor - Seeking Alpha - Fri Feb 20, 8:00AM CST
Every Friday morning, Seeking Alpha posts a calendar of the next week's expected biotech events to start a forward-looking conversation. Please be aware that dates and events can be subject to change. Please let us know in a comment or message if you...
LXRX: 8.21 (-0.10), AMRN: 2.41 (+0.02), HWAY: 12.34 (+0.31), HLS: 46.19 (+0.28), CYBX: 58.69 (+0.46), ESRX: 89.75 (+1.84), ECYT: 5.43 (+0.17), DXCM: 81.45 (+1.29), NSTG: 14.87 (+0.11), SRPT: 30.02 (+0.66), HZNP: 35.94 (+1.13), MDXG: 11.61 (+0.62), DEPO: 30.14 (+2.03), ANIK: 33.33 (+0.31), NKTR: 11.40 (+0.22), KERX: 9.81 (+0.11), ALIM: 4.56 (+0.15), EPZM: 23.42 (+0.45), AEGR: 18.48 (+0.36), MDRX: 13.25 (+0.22), ELGX: 15.10 (+0.19), NUVA: 46.77 (+0.55), HPTX: 45.99 (+0.02), GNMK: 8.69 (+0.15), MDVN: 106.81 (-2.19), HBIO: 5.34 (+0.16), ACAD: 43.94 (+1.76), ST: 50.45 (+0.13), RPTP: 14.51 (-0.34), FMI: 33.17 (+0.82), GMED: 25.39 (+0.42), JAZZ: 178.77 (+2.58), PTCT: 46.49 (+1.75), INFI: 10.19 (+0.23), ARNA: 4.29 (+0.04), EXEL: 3.68 (+0.25), NEO: 6.60 (+0.13), EXAS: 27.35 (+0.02), ALKS: 64.22 (+1.88), HTWR: 72.80 (-0.90), MNKD: 5.38 (+0.25), IPXL: 47.36 (+1.35), SQNM: 2.95 (+0.11), HALO: 22.78 (+0.38), ISIS: 53.50 (+0.42), CLVS: 80.02 (+1.82), BIO: 147.97 (+1.27), BIOS: 3.04 (+0.01), PCRX: 67.54 (+0.20)

David Horn Solomon assumes the role as President and Chief Executive Officer of Bionor Pharma ASA
GlobeNewswire - Fri Jan 09, 10:51AM CST
Bionor Pharma ASA (OSE:BIONOR) announces the appointment of Dr David Horn Solomon as new President and Chief Executive Officer. Dr Solomon will join the Company from NASDAQ OMX listed healthcare company Zealand Pharma A/S (NASDAQ:ZEAL), where he has served as President and CEO since September 2008.

UPDATE: Bionor Pharma Announces That the Combination of Vacc-4x + Revlimid(R) Is Well Tolerated and Increases CD4 Counts in People Living With HIV
Marketwired - Wed Nov 19, 3:29PM CST
Bionor Pharma ASA (OSLO: BIONOR)
CELG: 118.84 (+1.97)

Bionor Pharma Announces That the Combination of Vacc-4x + Revlimid(R) Is Safe and Increases CD4 Counts in People Living With HIV
Marketwired - Wed Nov 19, 2:35PM CST
Bionor Pharma ASA (OSLO: BIONOR)
CELG: 118.84 (+1.97)

Global Cervical Cancer Therapeutic Pipeline Review, H2 2014 - 35 Companies & 71 Drug Profiles
M2 - Wed Nov 19, 4:19AM CST
Research and Markets (http://www.researchandmarkets.com/research/4p52hn/cervical_cancer) has announced the addition of the "Cervical Cancer - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cervical Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cervical Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - F. Hoffmann-La Roche Ltd. - Sanofi - GlaxoSmithKline plc - Nektar Therapeutics - Inovio Pharmaceuticals, Inc. - Daiichi Sankyo Company, Limited - Amorfix Life Sciences Ltd. - MediGene AG - Nanotherapeutics, Inc. - Arbor Vita Corporation - Novartis AG - Chong Kun Dang Pharmaceutical Corp. - Taiho Pharmaceutical Co., Ltd. - Zeria Pharmaceutical Co Ltd - Genmab A/S - Advaxis, Inc. - 3SBio Inc. - Transgene SA - Antigen Express, Inc. - Shantha Biotechnics Limited - Bionor Pharma ASA - Azaya Therapeutics Incorporated - Merrimack Pharmaceuticals, Inc. - Genexine, Inc. - Genticel - Sirnaomics, Inc. - EyeGene, Inc. - Vaccibody AS - Wellstat Biologics Corporation - ISA Pharmaceuticals B.V. For more information visit http://www.researchandmarkets.com/research/4p...cal_cancer
MACK: 12.08 (+0.43), INO: 7.46 (+0.19), ADXS: 18.58 (+0.34), GSK: 42.45 (+0.65), NKTR: 11.40 (+0.22), NVS: 103.22 (+3.20)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

SLM Hit by Earnings Miss: Shareholders Eye Legal Action

When A Profit Turns To Loss There's a certain sting that comes with expecting a profit only to get smacked with a loss. You know the kind—like when SLM Corporation shareholders had their expectations shattered on October 22, 2026. They figured they'd see a $0.17 profit per share, but what landed instead was a $0.19 loss. That's a $0.36-per-share swing, enough to make...

Westlake Orchestrates Major Move for Watermark & Val-Chris

Texas Meets California in a Strategic Expansion There's a real synergy crossing state lines as Watermark Commercial Contractors sails into uncharted waters with its acquisition of Val-Chris Investments. Now, you might wonder why a Texas-based multifamily contractor would want to go after a private lender like Val-Chris. It's all about diversifying the portfolio, my...

Medical Device Manufacturing: $135B Market by 2031

Skyrocketing Demand in Medical Device Manufacturing You're looking at a market that's gearing up to hit a whopping $135.47 billion by 2031. That's a big leap from its $85.59 billion stature in 2026, showing a strong 9.6% compound annual growth rate (CAGR). Now, if that doesn't get your investor rollercoaster senses tingling, I don't know what will. Key Growth Drivers The...

Vertiv's SmartIT: The New AI Infrastructure Game-Changer

Taking AI Infrastructure Up a Notch Vertiv Holdings Co. (NYSE: VRT) is charging ahead with a solution that's bound to rattle the cages of status quo infrastructure deployments. Say hello to Vertiv™ SmartIT, a finely-tuned piece of kit that's pre-engineered to ease up the often painful process of high-density AI deployments across various environments—from homey...

Lear Capital Hits $5 Billion Milestone: Trust or Hype?

A Golden Milestone or Just Glitter? Lear Capital's announcement of surpassing $5 billion in precious metals transactions feels like one of those moments where you tilt your head and ask, "Is it really what it seems?" With nearly 150,000 customers and almost three decades of hustling in the glittering world of gold and silver, they've certainly carved out a name in the...

Denver Nonprofit Gains Seasoned Attorney for Board Expertise

The wheels of change have a new operator at the helm, and this time it's a seasoned attorney bringing three decades of grit and governance to Re-fined's mission. Michael W. Reagor has stepped up to serve on the Board of Directors for Re-fined, a nonprofit navigating the thorny path of human trafficking and sexual exploitation support. A Legal Ace in a Compassionate Arena...

US State Dept. & IICA: Strengthening Disaster Response

Bridging Borders to Tackle Disasters It seems like everyone and their grandma talks disaster aid, but when two giants like the US State Department's Bureau of Disaster and Humanitarian Response (DHR) and the Inter-American Institute for Cooperation on Agriculture (IICA) grab a coffee—real serious action is brewing. Why This Matters The partnership's not just talk. Let's...

NACCO Industries Preps for Q3 Results and Call

Anticipation Builds for NACCO's Q3 Financial Insights From the streets of Cleveland, NACCO Industries is ramping up to release their third quarter financial results for 2026. Mark your calendars for November 4, just after the market packs up for the day. Now, isn't it something to watch how these earnings reports seem to become a spectacle all their own? Promising...

AI's Rise: Worth Watching for M&A Strategy Insights

AI: The Hot Topic You Can't Ignore AI's rocking the boat like SEO did back in the day, folks. The Digital WOW is giving M&A Source® members a real scoop with their exclusive webinar, zeroing in on AI's potential seismic shifts in mergers and acquisitions. This should make any investor sit up and pay attention. AI's not just a tech buzzword anymore. It's like a strong cup...

TELUS Digital Named a Key Player in T&S Services 2026

Climbing the Ranks It’s not often you see a tech outfit surge ahead and pull off the kind of leaps TELUS Digital just managed. According to the Everest Group’s 2026 Trust and Safety Services PEAK Matrix® Assessment, TELUS Digital emerged as a Leader for the first time, riding high on advanced AI initiatives. Not just a pat on the back—that’s a big deal...